Literature DB >> 33210551

Human-derived osteoblast-like cells and pericyte-like cells induce distinct metastatic phenotypes in primary breast cancer cells.

Vera Mayo1, Annie C Bowles1,2,3, Laura E Wubker1, Ismael Ortiz1, Albert M Cordoves1, Richard J Cote4, Diego Correa2,3, Ashutosh Agarwal1,3.   

Abstract

Approximately 70% of advanced breast cancer patients will develop bone metastases, which accounts for ∼90% of cancer-related mortality. Breast cancer circulating tumor cells (CTCs) establish metastatic tumors in the bone after a close interaction with local bone marrow cells including pericytes and osteoblasts, both related to resident mesenchymal stem/stromal cells (BM-MSCs) progenitors. In vitro recapitulation of the critical cellular players of the bone microenvironment and infiltrating CTCs could provide new insights into their cross-talk during the metastatic cascade, helping in the development of novel therapeutic strategies. Human BM-MSCs were isolated and fractionated according to CD146 presence. CD146+ cells were utilized as pericyte-like cells (PLCs) given the high expression of the marker in perivascular cells, while CD146- cells were induced into an osteogenic phenotype generating osteoblast-like cells (OLCs). Transwell migration assays were performed to establish whether primary breast cancer cells (3384T) were attracted to OLC. Furthermore, proliferation of 3384T breast cancer cells was assessed in the presence of PLC- and OLC-derived conditioned media. Additionally, conditioned media cultures as well as transwell co-cultures of each OLCs and PLCs were performed with 3384T breast cancer cells for gene expression interrogation assessing their induced transcriptional changes with an emphasis on metastatic potential. PLC as well as their conditioned media increased motility and invasion potential of 3384T breast cancer cells, while OLC induced a dormant phenotype, downregulating invasiveness markers related with migration and proliferation. Altogether, these results indicate that PLC distinctively drive 3384T cancer cells to an invasive and migratory phenotype, while OLC induce a quiescence state, thus recapitulating the different phases of the in vivo bone metastatic process. These data show that phenotypic responses from metastasizing cancer cells are influenced by neighboring cells at the bone metastatic niche during the establishment of secondary metastatic tumors.

Entities:  

Keywords:  Cancer; bone; metastatic cascade; organs on chips; pericytes; tumor

Mesh:

Substances:

Year:  2020        PMID: 33210551      PMCID: PMC8024509          DOI: 10.1177/1535370220971599

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  144 in total

1.  c-Kit is required for growth and survival of the cells of origin of Brca1-mutation-associated breast cancer.

Authors:  J L Regan; H Kendrick; F-A Magnay; V Vafaizadeh; B Groner; M J Smalley
Journal:  Oncogene       Date:  2011-07-18       Impact factor: 9.867

2.  SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.

Authors:  Carminia Maria Della Corte; Claudio Bellevicine; Giovanni Vicidomini; Donata Vitagliano; Umberto Malapelle; Marina Accardo; Alessio Fabozzi; Alfonso Fiorelli; Morena Fasano; Federica Papaccio; Erika Martinelli; Teresa Troiani; Giancarlo Troncone; Mario Santini; Roberto Bianco; Fortunato Ciardiello; Floriana Morgillo
Journal:  Clin Cancer Res       Date:  2015-06-29       Impact factor: 12.531

3.  Cadherin-11 is expressed in invasive breast cancer cell lines.

Authors:  M J Pishvaian; C M Feltes; P Thompson; M J Bussemakers; J A Schalken; S W Byers
Journal:  Cancer Res       Date:  1999-02-15       Impact factor: 12.701

4.  Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival.

Authors:  Christine Gjerdrum; Crina Tiron; Torill Høiby; Ingunn Stefansson; Hallvard Haugen; Tone Sandal; Karin Collett; Shan Li; Emmet McCormack; Bjørn Tore Gjertsen; David R Micklem; Lars A Akslen; Carlotta Glackin; James B Lorens
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-28       Impact factor: 11.205

Review 5.  Chemokine biology in cancer.

Authors:  Fran Balkwill
Journal:  Semin Immunol       Date:  2003-02       Impact factor: 11.130

6.  MiR-204/ZEB2 axis functions as key mediator for MALAT1-induced epithelial-mesenchymal transition in breast cancer.

Authors:  Yuzhou Wang; Yijin Zhou; Zhicheng Yang; Baoying Chen; Wennan Huang; Yongyuan Liu; Ying Zhang
Journal:  Tumour Biol       Date:  2017-07

7.  Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients.

Authors:  Galatea Kallergi; Maria A Papadaki; Eleni Politaki; Dimitris Mavroudis; Vassilis Georgoulias; Sophia Agelaki
Journal:  Breast Cancer Res       Date:  2011-06-10       Impact factor: 6.466

8.  ABCB5-ZEB1 Axis Promotes Invasion and Metastasis in Breast Cancer Cells.

Authors:  Juntao Yao; Xuan Yao; Tao Tian; Xiao Fu; Wenjuan Wang; Suoni Li; Tingting Shi; Aili Suo; Zhiping Ruan; Hui Guo; Kejun Nan; Xiongwei Huo
Journal:  Oncol Res       Date:  2017-03-13       Impact factor: 5.574

9.  CD146 expression in human breast cancer cell lines induces phenotypic and functional changes observed in Epithelial to Mesenchymal Transition.

Authors:  Anne-Marie Imbert; Celine Garulli; Elodie Choquet; Myriam Koubi; Michel Aurrand-Lions; Christian Chabannon
Journal:  PLoS One       Date:  2012-08-30       Impact factor: 3.240

10.  Suppression of cell motility and metastasis by transfection with human motility-related protein (MRP-1/CD9) DNA.

Authors:  S Ikeyama; M Koyama; M Yamaoko; R Sasada; M Miyake
Journal:  J Exp Med       Date:  1993-05-01       Impact factor: 14.307

View more
  1 in total

Review 1.  Application of Microfluidic Systems for Breast Cancer Research.

Authors:  Zachary D Frankman; Linan Jiang; Joyce A Schroeder; Yitshak Zohar
Journal:  Micromachines (Basel)       Date:  2022-01-20       Impact factor: 2.891

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.